



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/70, 31/42	A1	(11) International Publication Number: WO 97/35590
		(43) International Publication Date: 2 October 1997 (02.10.97)

(21) International Application Number: PCT/US97/04743



(22) International Filing Date: 24 March 1997 (24.03.97)

(30) Priority Data:
08/622,260 25 March 1996 (25.03.96) US(71)(72) Applicant and Inventor: PLATT, Chris, E. [US/US];
14352 Riviera Drive, Huntington Beach, CA 92647 (US).(74) Agent: O'NEILL, James, G.; Suite 625, 3200 Bristol Street,
Costa Mesa, CA 92626-1810 (US).(81) Designated States: European patent (AT, BE, CH, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

With international search report.
With amended claims.

(54) Title: 10-AZA-9-DEOXY-11-DEOXY-ERYTHROMYCIN A AND DERIVATIVES COMBINED WITH SULFISOXAZOLE



(57) Abstract

Pharmaceutical compositions of an erythromycin derivative combined with sulfisoxazole according to structural formulas (I) and (II) where R is hydrogen; C₁-C₁₀ alkylcarbonyl, or substituted C₁-C₁₀ alkyl wherein the substituent is amino or cyano; R¹ and R² are independently hydrogen, hydroxyl or amino; and the pharmaceutical salts and esters thereof.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

APPLICATION

Of

CHRIS PLATT

For

UNITED STATES LETTERS PATENT

On

10-Aza-9-Deoxo-11-Deoxy-Erythromycin A and Derivatives Combined with Sulfisoxazole

TITLE: 10-Aza-9-Deoxo-11-Deoxy-Erythromycin A and Derivatives Combined with Sulfisoxazole

BACKGROUND OF THE INVENTION

Field Of The Invention

The present invention relates to a novel group of chemical compounds providing antibacterial activity, and which are useful in the therapy of bacterial infections in mammals. More specifically, the invention relates to compositions including the derivatives of the well-known antibiotic, erythromycin A.

Description of Related Art

The related art includes:

Tarpay et al, Antimicrobial Agents and Chemotherapy, Vol. 22, No. 1, pages 145-147 (1982).

Hughes et al., J. of Infectious Diseases, Vol. 170, No. 1, pages 906-911, (1994).

Doern et al., Antimicrobial Agents and Chemotherapy, Vol. 32, No. 2, pages 180-185 (1988).


U. S. Patents:

4,328,334 to Korbrehel et al	4,464,527 to Bright et al
4,465,674 to Bright et al	4,492,688 to Bright et al
4,512,982 to Hanske et al	4,517,359 to Kobrehel et al
4,526,889 to Bright et al	4,518,590 to Hanske et al
4,886,792 to Djokie	4,957,905 to Hunt et al

SUMMARY OF THE INVENTION

The erythromycin derivatives act by binding to the 50S ribosomal subunit of susceptible microorganisms and, thus, interfere with microbial protein synthesis. Nucleic acid synthesis is not affected. The sulfisoxazole inhibits bacterial synthesis of dihydrofolic acid by preventing the

condensation of the pteridine with para-aminobenzoic acid through competitive inhibition of the enzyme dihydropteroate synthetase. After absorption the erythromycin derivative is largely bound to plasma proteins and readily diffuses into most body fluids. Rapid distribution of erythromycin derivative into tissues and high concentration within cells results in higher concentrations in tissues than in serum or plasma. Erythromycin derivative seems to concentrate in fibroblasts and phagocytes as demonstrated by in vivo incubation techniques. Such derivatives are modifications of the well-known antibiotic, erythromycin A, having the following structure:



The erythromycin derivatives of the present invention relate to the compounds of the following structure and derivatives thereof, which form a novel class of 14-membered azalides characterized in that the heterocyclic nitrogen atom is situated at the 10 position. The inventive step in the present invention is that these compounds are combined with sulfoxazole for enhanced antibacterial activity. The present invention provides for novel pharmaceutical compositions and methods for their use as antibacterial agents.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

An important challenge in regards to antibiotics, is how to avoid the problem of pathological resistance to these medications. By combining two different antibiotics, each having different mechanisms of action, but which work synergistically together this problem can be overcome. The present invention stems from the discovery that certain erythromycin derivatives are easily

tolerated by patients without causing gastrointestinal disturbances. Additionally when combined with sulfisoxazole, resistance to *Enterococcus Faecalis*, methacillin-resistant staphylococci, and erythromycin resistant gram-positive strains is achieved. The inventive combination provides protection from a greater antibacterial spectrum than either erythromycin or sulfisoxazole alone. Thus, this new invention not only saves lives by providing a combination that overcomes medication resistance but is more easily tolerated without stomach upset and vomiting; side effects experienced by many people taking erythromycin alone.

Specifically the basis for the present invention is the pharmaceutical composition of an erythromycin derivative combined with acetylsulfisoxazole according to the structural formulas shown in Claim 1 below, where R is hydrogen; C1-C10 alkylcarbonyl, or substituted C1-C10 alkyl wherein said substituent is amino or cyano; and R¹ and R² are independently hydrogen, hydroxyl or amino; and including the pharmaceutical salts and esters thereof. Chemically acetylsulfisoxazole is N-(3,4,-Dimethyl-5-isoxazole)-N-sulfanyllactamide. Sulfisoxazole, where the acetyl group is replaced by H is an alternative substitution in the invention. Alternative possibilities for the erythromycin derivative include, but are not limited to, the structural formulas as shown in either Claim 3 where R is methyl, R¹ is H and R², in Claim 5 where R is amino alkyl carbonyl, R¹ is H and R² is OH, and in Claim 6 where R is cyano, R¹ is an amino group, and R² is H.

In an alternate embodiment, the composition of the present invention may be formulated wherein the erythromycin derivative has the general structural formula as shown below in Claim 2, including the pharmaceutically acceptable salts, esters and metal complexes thereof, wherein R¹ is hydrogen, C1-C10 alkyl carbonyl or unsubstituted or substituted C1-C10 alkyl wherein the substituent is amino or cyano; R² and R³ are hydrogen; R² and R³ together are oxo; R⁴ is hydrogen or C1-C10 alkylcarbonyl; R⁵ and R⁶ are independently hydrogen, hydroxy or amino; R⁵ and R⁶ together are oxo or oximino; R⁷ and R⁸ are independently hydrogen, C1-C10 alkyl or phenylsulfonyl; R⁹ is hydrogen, or C1-C10 alkylcarbonyl, and R¹⁰ is hydrogen. Examples of operable substitutions for the nine variables include the following:


R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹
CH ₃	H	H	H	H	OH	H	H	H
CH ₃	H	H	H	H	OH	CH ₃	CH ₃	H
CH ₃	H	H	CH ₃	H	OH	H	H	H

In formulating the combination of the present invention it has been found that the mixture ratio by weight, of erythromycin to sulfisoxazole, may range from 100:1 to as much as 1:1, and even trace amounts of sulfisoxazole may be operative. The preferred ratio is 100:38. The erythromycin and sulfisoxazole are prepared following standard laboratory procedures and processes that all competent workers in the field of the present invention will know.

The various alternative formulations of the present invention may take the form of a compressed pill, a powder in an easy to swallow caplet, or even as a fluid dissolved in a liquid such as water. In all cases, the formulation is to be taken orally.

CLAIMS

1. A pharmaceutical composition of an erythromycin derivative combined with acetylsulfisoxazole according to the structural formulas:




where R is hydrogen;

C1-C10 alkylcarbonyl, or substituted C1-C10 alkyl wherein said substituent is amino or cyano;

R1 and R2 are independently hydrogen, hydroxyl or amino;

and the pharmaceutical salts and esters thereof.

2. A pharmaceutical composition of a erythromycin derivative combined with acetylsulfisoxazole according to the structural formula:



and the pharmaceutically acceptable salts, esters and metal complexes thereof, wherein

R^1 is hydrogen,

C1-C10 alkylcarbonyl or unsubstituted or substituted

C1-C10 alkyl [where] wherein said substituent is amino or cyano;

R^2 and R^3 are hydrogen;

R^2 and R^3 together are oxo;

R^4 is hydrogen or C1-C10 alkylcarbonyl;

R^5 and R^6 are independently hydrogen, hydroxy or amino;

R^5 and R^6 together are oxo or oximino;


R^7 and R^8 are independently hydrogen, C1-C10 alkyl or phenylsulfonyl;

R^9 is hydrogen, or C1-C10 alkylcarbonyl,

R^{10} is hydrogen, and


R^{11} is hydrogen or acetyl.

3. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:




wherein R is methyl, R^1 is H and R^2 is OH.

4. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:



wherein R is amino alkyl carbonyl, R¹ is H and R² is OH.

5. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:





wherein R is cyano, R¹ is an amino group, and R² is H.

AMENDED CLAIMS

[received by the International Bureau on 12 August 1997 (12.08.97);
original claims 1-5 replaced by amended claims 1-5 (3 pages)]

1. A pharmaceutical composition of an erythromycin derivative combined with acetylsulfisoxazole according to the structural formulas:




where R is hydrogen;

C_1 - C_{10} alkylcarbonyl, or substituted C_1 - C_{10} alkyl wherein said substituent is amino or cyano;

R^1 and R^2 are independently hydrogen, hydroxyl or amino; and the pharmaceutical salts and esters thereof.

2. A pharmaceutical composition of a erythromycin derivative combined with acetylsulfisoxazole according to the structural formula:



and the pharmaceutically acceptable salts, esters and metal complexes thereof. wherein

R^1 is hydrogen,

C_1 - C_{10} alkylcarbonyl or unsubstituted or substituted.

C_1 - C_{10} alkyl [where] wherein said substituent is amino or cyano;

R^2 and R^3 are hydrogen;

R^2 and R^3 together are oxo;

R^4 is hydrogen or C_1 - C_{10} alkylcarbonyl;

R^5 and R^6 are independently hydrogen, hydroxy or amino;

R^5 and R^6 together are oxo or oximino;


R^7 and R^8 are independently hydrogen, C_1 - C_{10} alkyl or phenylsulfonyl;

R^9 is hydrogen, or C_1 - C_{10} alkylcarbonyl,

R^{10} is hydrogen, and


R^{11} is hydrogen or acetyl.

3. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:




wherein R is methyl, R^1 is H and R^2 is OH.

4. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:



wherein R is amino alkyl carbonyl, R^1 is H and R^2 is OH.

5. The composition as claimed in claim 1, wherein the erythromycin derivative has the structural formula:



wherein R is cyano, R¹ is an amino group, and R² is H.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/04743

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/70, 31/42

US CL : 514/29, 378

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/29, 378

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
noneElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
cas-online, aps

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Antimicrobial Agents and Chemotherapy, Volume 22, Number 1, issued July 1982, Tarpay et al., "In Vitro Activity of Antibiotics Commonly Used in the Treatment of Otitis Media Against Streptococcus pneumoniae Isolates with Different Susceptibilities to Penicillin", pages 145-147, see the entire document.	1-5
Y	Antimicrobial Agents and Chemotherapy, Volume 32, Number 2, issued February 1988, Doern et al., "National Collaborative Study of the Prevalence of Antimicrobial Resistance among Clinical Isolates of Haemophilus influenzae", pages 180-185, see the entire document.	1-5

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

13 MAY 1997

Date of mailing of the international search report

80 JUN 1997.

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231Authorized officer
KEVIN WEDDINGTON

Facsimile No. (703) 305-3230

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/04743

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	The Journal of Infectious Diseases, Volume 170, Number 1, issued 1994, Hughes et al., "Relative Potency of 10 Drugs with Anti-Pneumocystis carinii Activity in an Animal Model", pages 906-911.	1-5
Y	M. Windholz et al., "THE MERCK INDEX, AN ENCYCLOPEDIA OF CHEMICALS, DRUGS, AND BIOLOGICALS, TENTH EDITION", published 1983 by Merck & CO., Inc. (N.J.), page 16, see number 104.	1-5

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.